IMPORTANCE Several studies have reported antidepressant effects of anti-inflammatory treatment; however, the results have been conflicting and detrimental adverse effects may contraindicate the use of anti-inflammatory agents.
with depression (SMD, −0.54; 95% CI, −1.08 to −0.01; I 2 = 68%) and depressive symptoms (SMD, −0.27; 95% CI, −0.53 to −0.01; I 2 = 68%). The heterogeneity of the studies was not explained by differences in inclusion of clinical depression vs depressive symptoms or use of NSAIDs vs cytokine inhibitors. Subanalyses emphasized the antidepressant properties of the selective cyclooxygenase 2 inhibitor celecoxib (SMD, −0.29; 95% CI, −0.49 to −0.08; I 2 = 73%) on remission (OR, 7.89; 95% CI, 2.94 to 21.17; I 2 = 0%) and response (OR, 6.59; 95% CI, 2.24 to 19.42; I 2 = 0%). Among the 6 studies reporting on adverse effects, we found no evidence of an increased number of gastrointestinal or cardiovascular events after 6 weeks or infections after 12 weeks of anti-inflammatory treatment compared with placebo. All trials were associated with a high risk of bias owing to potentially compromised internal validity.
CONCLUSIONS AND RELEVANCE Our analysis suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms without increased risks of adverse effects. However, a high risk of bias and high heterogeneity made the mean estimate uncertain. This study supports a proof-of-concept concerning the use of anti-inflammatory treatment in depression. Identification of subgroups that could benefit from such treatment might be warranted.
Thus, studies have investigated whether the use of antiinflammatory agents could improve the antidepressant response. Nonsteroidal anti-inflammatory drugs (NSAIDs), in particular the selective cyclooxygenase 2 (COX-2) inhibitor celecoxib, 6 and cytokine inhibitors 7 have shown promising results in clinical trials. Nonsteroidal anti-inflammatory drugs and cytokine inhibitors exert anti-inflammatory effects by inhibiting proinflammatory cytokines. Cytokine inhibitors act directly on these cytokines, 7 whereas NSAIDs inhibit the enzyme COX-2, 6 which is responsible for cytokine production.
However, sample sizes in most clinical trials were small and the results were conflicting, particularly in NSAID studies; observational trials 8, 9 have associated NSAIDs with worse antidepressant treatment effects. Several adverse effects associated with anti-inflammatory treatment have been well described [10] [11] [12] and should be considered in the evaluation of benefits and risks. Nevertheless, the observed significant effects in small study groups support the evidence of potential antidepressant effects of anti-inflammatory treatment. Two recent meta-analyses have associated celecoxib add-on treatment 13 and NSAID monotherapy 14 with antidepressant effects. However, these meta-analyses 13, 14 did not include an assessment of potential bias for the included studies, making an overall assessment based solely on pooling of effect sizes problematic. It is important to evaluate the overall effect of anti-inflammatory intervention, including a broader range of studies, and compare a potential antidepressant effect with the risk for adverse effects. Trials with unclear or inadequate methodologic quality may be associated with risk of bias (systematic error) compared with trials using adequate methods, possibly leading to overestimation of intervention benefits and underestimation of harms. 15 In addition, the width of clinical findings indicates the importance of not only investigating the effect of anti-inflammatory agents on depression 13 or depressive symptoms 14 and one compound 13, 14 but also including the entire spectrum of individuals with depressive symptoms and the entire range of anti-inflammatory agents. The objectives of this systematic review and metaanalysis were to investigate the antidepressant effect of anti-inflammatory treatment and to assess possible adverse effects of these interventions in adults with depressive symptoms or depression. Investigations of the concomitant use of antidepressants and anti-inflammatory agents are of major public concern because anti-inflammatory agents, in particular NSAIDs, are frequently used by individuals receiving antidepressants, probably owing to the bidirectional relationship between depression and pain. 16 
Methods
The current meta-analysis aimed to include all evidence from clinical trials that have investigated anti-inflammatory treatment in depression, regardless of whether the antiinflammatory treatment was used alone or as add-on therapy. We were interested in both antidepressant treatment effects and adverse events among adults.
Eligibility Criteria
Only randomized clinical trials were included in the metaanalysis (ie, the allocation of participants to intervention and comparison groups was described as randomized). We assessed studies investigating patients of both sexes older than 17 years. Patients could have either a diagnosis of depression or experience depressive symptoms that did not meet the criteria for depression. Because we were interested in the effect of anti-inflammatory treatment on depressive symptoms in general, trials were included regardless of concomitant disease among the patients or whether the trials included the measurement of depressive symptoms in otherwise healthy individuals. Depression was diagnosed according to a diagnostic system (Research Diagnostic Criteria, International Classification of Diseases, or DSM-IV). Depressive symptoms were rated with clinician-rated scales or self-report questionnaires (eg, Patient Health Questionnaire-9 and Hospital Anxiety and Depression Scale-Depression). The trials had to allocate participants to (1) an anti-inflammatory drug or a control group (eg, placebo or treatment as usual) or (2) an anti-inflammatory drug as add-on treatment (eg, a selective serotonin reuptake inhibitor [SSRI] with an anti-inflammatory drug vs an SSRI with a placebo). We defined anti-inflammatory treatment as NSAIDs, COX-2 inhibitors, proinflammatory cytokine inhibitors, and minocycline hydrochloride. 
Search Methods for Identification of Trials

Data Extraction
Data were extracted independently (O.K., with assistance from J.K.) using a pre-piloted structured form. The extractors were not blinded to the study results, authors, or institutions. In addition to bibliographic information, data extraction included quality assessment, description of the participants, description of the intervention and control groups, psychometric data, and outcomes. We contacted authors of the articles identified by e-mail to learn details missing from the Methods and Results sections of the reports and deter-
Outcome Measures
Primary outcome measures included (1) a significant reduction in depressive symptoms measured on a continuous scale at the end of an intervention, (2) response (ie, a binary outcome of the proportion of participants in each intervention group who were defined as having responded to treatment [50% reduction in depression severity]) measured at the end of the intervention, (3) serious adverse effects including gastrointestinal and cardiovascular events for NSAIDs and infections for all other drugs, and (4) remission in patients with depression (ie, a binary outcome of the proportion of participants in each intervention group whose condition was classified, for example, as a Hamilton Scale for Depression score <7 at the end of an intervention). Some trials had several intervention groups, which we analyzed by pooling data from the experimental groups and comparing them with data from the control group. Secondary outcome measures included (1) nonserious adverse effects, (2) depressive symptoms measured on a continuous scale at maximal follow-up, and (3) remission at maximal follow-up.
Assessment of Bias
The bias risks of the randomized clinical trials included were assessed (J.K.). Based on the recommendations in the Cochrane Handbook for Systematic Reviews of Interventions 17 and methodologic studies, [18] [19] [20] [21] we extracted data regarding quality for 5 domains. Sequence generation was considered adequate if the authors described a random component. Allocation concealment was adequate if it was justified that neither participants nor investigators could foresee the assignment. Blinding of outcome assessors was adequate if the trial was characterized as double-blind; however, blinding of outcome assessors was not inferred from the term double-blind, and in cases in which the outcome was self-reported, participants were considered outcome assessors. Analyses were considered intention to treat if missing data were handled by adequate methods (mixed models, multiple imputations, or similar methods) or if no missing data were observed. For-profit bias was considered low if the trial appeared to be free of industry sponsorship or any other kind of for-profit support. Trials were assessed as having a low risk of bias if the review of all of the individual domains was considered to show a low risk of bias. Trials assessed as having uncertain risk of bias or high risk of bias in one or more of the individual domains were considered trials with a high risk of bias.
Statistical Analysis
We estimated a standardized mean difference (SMD) for each study using the Cohen d test. The SMD is the mean difference in the depression score between the intervention and control groups divided by the pooled SD of the distribution of the score used in the study. The result is a unitless effect-size measure readily comparable to other studies using similar measures of outcome. By convention, effect sizes of 0.2, 0.4, and 0.8 are considered small, medium, and large, respectively. For dichotomous variables, we calculated the relative risks with 95% CIs. We decided a priori to use a random-effects analysis because of expected heterogeneity due to different treatment regimens and patient populations. In addition, we calculated the pooled odds ratio (OR) for response and remission in the included trials.
The χ 2 test for heterogeneity provided an indication of between-trial heterogeneity. In addition, the degree of heterogeneity observed in the results was quantified using the I 2 statistic, 22 which can be interpreted as the percentage of variation observed between the trials attributable to between-trial differences rather than sampling error (chance). We used RevMan, version 5.2, for calculations. 23 
Subgroup Analysis
We decided a priori to perform subanalyses of both depression and depressive symptoms and of the selective COX-2 inhibitor celecoxib. Subgroup differences were tested using RevMan, version 5.2. This method is based on fixed-effects analysis using the inverse variance method.
Discrepancies From the Protocol
We decided to include response as an outcome.
We were not able to analyze the effect of baseline cytokine levels, since only 1 trial reported baseline C-reactive protein (CRP) levels 24 and 1 trial reported baseline interleukin 6 (IL-6) levels.
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Results
Search Results and Study Characteristics
Using our search criteria, 1500 records were identified, of which 53 were assessed for abstract and full-text inspection (eFigure 1 in the Supplement). We included 10 publications comprising 14 randomized clinical trials investigating the antidepressant effects of anti-inflammatory treatment in 6262 adults. Ten trials investigated NSAIDs, 4 as add-on treatment, 6,25-27 and 6 as monotherapy ( 
Treatment Effect of Anti-inflammatory Intervention: Primary Outcomes
For the study by Tyring et al, 7 we had information only for performing analyses on response (50% reduction in depression severity) and adverse effects. In 11 of the 13 available trials, antiinflammatory treatment was found to yield antidepressant effects with a pooled effect estimate of −0.34 (95% CI, −0.57 to −0.11; P = .004) (Figure 1) . However, this effect estimate was associated with high heterogeneity, reflected by I 2 = 90%. The overall result from fixed-effects analysis was −0.20 (95% CI, −0.26 to −0.14; P < .001).
cluding 5255 patients (SMD, −0.27; 95% CI, −0.53 to −0.01; P = .05; I 2 = 68%) (Figure 1 ). No significant subgroup difference between depression and depressive symptoms could be detected (P = .37). hibitors with −0.38 (95% CI, −0.88 to 0.12; P = .14; I 2 = 85%
[n = 2004]) (Figure 2) . No subgroup differences could be detected (P = .67). By visual inspection of the forest plot on NSAIDs in Figure 2 , the effect estimate obtained in the trial by Fields et al, 28 the only study on healthy individuals, was markedly different. After excluding this study, the pooled effect estimates remained similar (SMD, −0.37; 95% CI, −0.57 to −0.18; P < .001) but with a smaller heterogeneity (I 2 = 76%). 
Bias of Included Trials
As reported in Table 2 , all effects estimated from trial reports were associated with a high risk of bias. Eleven of the 14 trials did not report adequate sequence generation. In each of the categories used (allocation concealment, intention-to-treat analysis, and for-profit bias), most trials were judged to have a high risk of bias. Blinded outcome assessment was the only domain in which all studies showed a low risk of bias.
Subanalyses
All studies investigating NSAIDs included celecoxib. Celecoxib treatment in general could be associated with a trend toward superiority (10 trials 
Discussion
To our knowledge, the present meta-analysis is the largest study on anti-inflammatory treatment for depressive symptoms to date, combining data on anti-inflammatory add-on treatment and monotherapy. Fourteen randomized clinical trials with a total of 6262 patients were evaluated. Antiinflammatory treatment showed a beneficial effect on depressive symptoms. However, this estimate was associated with a high level of heterogeneity. The type of depression, somatic comorbidity, and type of medication or treatment (ie, monotherapy or add-on therapy) did not explain the differences noted in effect estimation. Nonsteroidal anti-inflammatory drugs were associated with a better antidepressant effect in general, with 9 of 10 trials favoring NSAIDs, whereas a statistical trend was observed favoring cytokine inhibitors among 4 studies, but the results remained heterogeneous. Subanalyses of celecoxib showed improved antidepressant effects with little heterogeneity, in particular with add-on treatment.
Our analyses did not associate NSAIDs or cytokine inhibitors with an increased risk for adverse effects. However, not the present meta-analysis was restricted to studies with shortterm treatment duration, since evaluation of long-term effects was not possible. In addition, the present systematic review included only 14 trials, making detection of publication bias problematic, 31 and we cannot exclude the possibility of unpublished trial results. Finally, the antidepressant effect of NSAIDs may be mediated via their effects on underlying somatic diseases. However, the antidepressant effect of NSAIDs has been shown 14 to be independent of their pain-relieving effect. Hence, our results should be interpreted with caution. Nonetheless, it is possible that specific subgroups would benefit more from anti-inflammatory intervention, such as patients with low-grade inflammation 24 or comorbid inflammatory diseases. 14 be most pronounced among patients with increased proinflammatory markers.
Antidepressant Effects of Anti-inflammatory Agents
To our knowledge, the present study is the first to analyze the overall effect and emphasize the potential antidepressant treatment effects of celecoxib, with and without concomitant antidepressant medication. The effect is considered large and thus clinically relevant. The potential importance of an active inflammatory state on the antidepressant effects of anti-inflammatory agents is supported by studies 14, 33 on selective COX-2 inhibitor monotherapy among patients with osteoarthritis. In one trial, 28 12 months of monotherapy with celecoxib or naproxen in healthy individuals 70 years or older did Adverse Effects of Anti-inflammatory Agents
The potential antidepressant treatment effects of antiinflammatory strategies should always be balanced against the risk for adverse effects. Nonsteroidal anti-inflammatory drugs increase the risk for gastrointestinal 10 and cardiovascular adverse effects, 11 whereas cytokine inhibitors increase the risk for infections. 12 We observed no increased risks of these important adverse effects; however, not all of the studies included in the present meta-analysis reported on adverse effects and treatment lasted only 6 to 12 weeks ( and modulation of the mineralocorticoid receptor 49 also improved the effects of antidepressants in randomized, placebocontrolled trials. However, the anti-inflammatory effects of these agents are speculative and were therefore not included in the present meta-analysis. Synthetic cortisol compounds have shown acute antidepressant effects, 50,51 but because of cortisol's various effects, these results cannot exclusively be ascribed to an anti-inflammatory effect.
Perspectives
Compelling evidence suggests an association between depression and inflammation, but no causal link with specific inflammation markers, such as CRP, has been established. 52 Research should be prioritized to identify markers and the underlying cellular mechanisms to support identification of relevant subgroups that would benefit from anti-inflammatory treatment or potentially new antidepressant drugs with a targeted effect on inflammation. Different approaches are of particular interest. First, subgroups of depressed patients with elevated inflammatory markers (CRP and IL-6) have been associated with higher rates of treatment response. 24,25 Second, patients with depressive symptoms as well as comorbid pain-related 14, 33 or inflammatory 7,29,30 disorders responded better to anti-inflammatory treatment. Third, it should be further elucidated whether anti-inflammatory treatment effects could be linked to a reduction of specific depressive symptoms. Finally, it is interesting that NSAIDs, particularly celecoxib, have been associated with treatment effects in schizophrenia 53,54 and bipolar disorder. 55 This association
indicates that immune-related factors might be implicated and that anti-inflammatory treatment strategies would be relevant to evaluate in a larger spectrum of psychiatric disorders.
Conclusions
Our results indicate a proof-of-concept concerning the use of anti-inflammatory agents in the antidepressant treatment regimen and thus provide support for the speculated link between inflammation and subgroups of patients with major depressive disorder. In this meta-analysis, the use of NSAIDs was associated with an improved antidepressant treatment response without an increased risk for well-known adverse effects. In particular, add-on treatment with celecoxib improved antidepressant effects, remission, and response. Cytokine inhibitors were studied in few trials, and no significantly better antidepressant treatment effects were found compared with placebo. Our findings emphasize the need for identifying subgroups that may benefit more from anti-inflammatory intervention, such as patients with elevated inflammatory markers or a somatic comorbidity. Specific agents, particularly celecoxib, showed promising results and should therefore be investigated in high-quality randomized clinical trials. Such trials should carefully report on adverse effects and include long-term follow-up.
